Add to Calendar 5/5/2022 8:30:00 AM 5/5/2022 8:30:00 PM 2022 State of Possible Conference MassBio's annual State of Possible Conference celebrates how the life sciences make the impossible possible. We will tap today’s brightest minds for engaging conversations on the latest developments in our industry, key insights from the past year, and building a better future for patients around the world. This year's conference will explore the theme "The Massachusetts BioPharma Ecosystem in the Post- Covid Era."

Join MassBio and more than 500 attendees for a day of networking, keynotes, and panel discussions from some of the most inspiring voices in the industry, culminating in a reception celebrating the life sciences community. This is our most popular event so you will want to reserve your spot early.
Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Head, Global Medical Affairs Oncology, Takeda
Awny Farajallah M.D. joined Takeda in July 2021 as the Head of Global Medical Affairs Oncology. He brings over 25 years of combined experience in both academic and industry settings related to clinical research/development and medical affairs across multiple therapeutic areas. Awny joins us from Ipsen, where he was Senior Vice President, Medical Affairs, North America. As a key North America Leadership Team and Global Medical Affairs Leadership Team member, Awny was responsible for providing strategic leadership and direction for all facets of the Medical Affairs organization in North America. During his tenure, Awny also led efforts to enhance Medical Affairs capabilities with the goal of broadening the impact to patients through medical stakeholder partnerships across Oncology, Neuroscience and Rare Disease. Prior to joining Ipsen, Awny served as Vice President and Head of US Medical Affairs at Bristol Myers Squibb, where he led functions such as field medical, disease areas, medical education, biomarkers, promotional material review, portfolio strategy, as well as strategic collaborations across oncology, immunoscience, cardiovascular, neurology and mature brands. Awny has led multiple successful launches in Immuno-oncology and hematology for Opdivo and Yervoy and Sprycel. He also was the clinical development lead for hematological malignancies in leukemia and multiple myeloma. He also led the global medical and clinical development teams for HIV including Reyataz global life cycle management and business development. Awny earned his M.D. from Cairo University and completed an Internal Medicine residency and Infectious Diseases fellowship at the University of Arkansas for Medical Sciences and New Jersey Medical School, respectively.

Brought to you by